MedTrace Logo

Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury

NCT05886998 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2024-12-12

No results posted yet for this study

Summary

This study aims to examine the effects of nebulized heparin on the clinical outcomes in adult patients suffering smoke inhalation injury.

Patients will be randomized to receive nebulized heparin or an equal volume of normal saline for 14 days and the incidence of acute lung injury will be compared in either group.

Conditions

  • Smoke Inhalation Injury
  • Acute Lung Injury

Interventions

DRUG

Heparin

Heparin sodium (Generic, 5000 IU/ml ampoules)

OTHER

Normal Saline

0.9% sodium chloride solution (normal saline)

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Sameh M Hakim, MD · Ain Shams University Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-06-03
Completion
2024-06-03

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05886998 on ClinicalTrials.gov